Relmada Therapeutics

Contributing Author

Recent Articles by Relmada Therapeutics

Nov-07	Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 RLMD GlobeNewswire
Nov-04	Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants RLMD GlobeNewswire
Nov-04	Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer RLMD GlobeNewswire
Oct-07	Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 RLMD GlobeNewswire
Sep-16	Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement RLMD GlobeNewswire
Sep-10	Relmada Issues Mid-Year CEO Letter to Shareholders RLMD GlobeNewswire
Aug-07	Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC RLMD GlobeNewswire
Jul-31	Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 RLMD GlobeNewswire
Jul-15	Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 RLMD GlobeNewswire
Jun-17	Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology RLMD GlobeNewswire
May-12	Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update RLMD GlobeNewswire
May-08	Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 RLMD GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.